{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T04:27:18Z","timestamp":1785644838675,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.pcad.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T19:25:07Z","timestamp":1749497107000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is it safe to use class 1C antiarrhythmic drugs in patients with coronary artery disease and\/or cardiomyopathy?"],"prefix":"10.1016","volume":"91","author":[{"given":"Peter G.","family":"Pantlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Bharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2025.06.001_bb0005","author":"Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia (FLECA-ED)"},{"issue":"5","key":"10.1016\/j.pcad.2025.06.001_bb0010","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/clc.23983","article-title":"Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States","volume":"46","author":"Turakhia","year":"2023","journal-title":"Clin Cardiol"},{"issue":"16","key":"10.1016\/j.pcad.2025.06.001_bb0015","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jacc.2024.07.014","article-title":"Minimum national prevalence of diagnosed atrial fibrillation inferred from California acute care facilities","volume":"84","author":"Noubiap","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.06.001_bb0020","series-title":"Heart Disease and Stroke Statistics - 2023 Update: A Report from the American Heart Association","volume":"147","author":"Tsao","year":"2023"},{"issue":"6","key":"10.1016\/j.pcad.2025.06.001_bb0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cpcardiol.2017.06.001","article-title":"Current evidence-based understanding of the epidemiology, prevention, and treatment of atrial fibrillation","volume":"43","author":"Rogers","year":"2018","journal-title":"Curr Probl Cardiol"},{"issue":"14","key":"10.1016\/j.pcad.2025.06.001_bb0030","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pcad.2025.06.001_bb0035","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2022.03.337","article-title":"The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review","volume":"79","author":"Camm","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.pcad.2025.06.001_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.118.011560","article-title":"Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines\u2014heart failure","volume":"8","author":"Kelly","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.pcad.2025.06.001_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCEP.119.007414","article-title":"Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and Meta-analysis of randomized controlled trials","volume":"12","author":"Asad","year":"2019","journal-title":"Circ Arrhythmia Electrophysiol"},{"issue":"9","key":"10.1016\/j.pcad.2025.06.001_bb0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jacc.2021.06.038","article-title":"Cryoballoon ablation as initial treatment for atrial fibrillation: JACC state-of-the-art review","volume":"78","author":"Andrade","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2025.06.001_bb0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2212540","article-title":"Progression of atrial fibrillation after cryoablation or drug therapy","volume":"388","author":"Andrade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2025.06.001_bb0060","series-title":"Guideline for the Management of Patients with Atrial Fibrillation (AFib)","volume":"9","author":"Haque","year":"2014"},{"issue":"6","key":"10.1016\/j.pcad.2025.06.001_bb0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The cardiac arrhythmia suppression trial (CAST) investigators","volume":"321","author":"Akhtar","year":"1989","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2025.06.001_bb0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jce.14335","article-title":"Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease","volume":"31","author":"Pantlin","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2025.06.001_bb0075","series-title":"ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2023"},{"key":"10.1016\/j.pcad.2025.06.001_bb0080","series-title":"AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary","volume":"130","author":"January","year":"2014"},{"issue":"20","key":"10.1016\/j.pcad.2025.06.001_bb0085","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.1993.03510200057032","article-title":"Mortality following ventricular arrhythmia suppression by Encainide, flecainide, and Moricizine after myocardial infarction: the original design concept of the cardiac arrhythmia suppression trial (CAST)","volume":"270","author":"Epstein","year":"1993","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.pcad.2025.06.001_bb0090","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1161\/01.CIR.90.6.2843","article-title":"Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the cardiac arrhythmia suppression trial (CAST)","volume":"90","author":"Anderson","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pcad.2025.06.001_bb0095","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jacep.2024.01.021","article-title":"Class 1C Antiarrhythmics for premature ventricular complex suppression in nonischemic cardiomyopathy with implantable cardioverter-defibrillators","volume":"10","author":"Raad","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"10.1016\/j.pcad.2025.06.001_bb0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/01.CIR.81.3.1123","article-title":"CAST and beyond: implications of the cardiac arrhythmia suppression trial","volume":"81","author":"Akhtar","year":"1990","journal-title":"Circulation"},{"issue":"Si","key":"10.1016\/j.pcad.2025.06.001_bb0105","doi-asserted-by":"crossref","first-page":"I47","DOI":"10.1093\/eurheartjsupp\/suac073","article-title":"The many NOs to the use of Class IC antiarrhythmics: weren\u2019t the guidelines too strict?","volume":"24","author":"Turturiello","year":"2022","journal-title":"Eur Hear J Suppl"},{"issue":"16","key":"10.1016\/j.pcad.2025.06.001_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163696","article-title":"Flecainide in ventricular arrhythmias: from old myths to new perspectives","volume":"10","author":"Lavalle","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.pcad.2025.06.001_bb0115","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0002-9149(02)02867-9","article-title":"Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (the European Rythmol\/Rytmonorm atrial fibrillation trial [ERAFT] study)","volume":"90","author":"Meinertz","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.06.001_bb0120","series-title":"A Reassessment of the Safety of 1C Antiarrhythmics in Coronary Artery Disease","author":"Pantlin","year":"2018"},{"key":"10.1016\/j.pcad.2025.06.001_bb0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10840-022-01186-0","article-title":"Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation","volume":"65","author":"Cay","year":"2022","journal-title":"J Interv Card Elecrophysiology"},{"issue":"7","key":"10.1016\/j.pcad.2025.06.001_bb0130","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jacep.2022.12.021","article-title":"The feasibility and safety of flecainide use among patients with varying degrees of coronary disease","volume":"9","author":"Kiani","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"10.1016\/j.pcad.2025.06.001_bb0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0735-1097(96)00555-4","article-title":"Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study","volume":"29","author":"Faber","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2025.06.001_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.hrthm.2017.12.018","article-title":"Class IC antiarrhythmic drugs for suspected premature ventricular contraction\u2013induced cardiomyopathy","volume":"15","author":"Hyman","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2025.06.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-024-02394-6","article-title":"Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator","author":"Zylla","year":"2024","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.06.001_bb0150","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/pace.12426","article-title":"Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality","volume":"37","author":"Chung","year":"2014","journal-title":"PACE - Pacing Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2025.06.001_bb0155","series-title":"Diagnosis and Management of Hypertrophic Cardiomyopathy: Updated Guidelines From the ACC\/AHA","volume":"105","author":"Leggit","year":"2022"},{"key":"10.1016\/j.pcad.2025.06.001_bb0160","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00380-014-0534-3","article-title":"Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide","volume":"30","author":"Haruki","year":"2015","journal-title":"Heart Vessels"},{"issue":"11","key":"10.1016\/j.pcad.2025.06.001_bb0165","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.pcad.2025.06.001_bb0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/pace.12250","article-title":"Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy","volume":"37","author":"Ermakov","year":"2014","journal-title":"PACE - Pacing Clin Electrophysiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:49:05Z","timestamp":1776833345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062025000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"alternative-id":["S0033062025000805"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.06.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it safe to use class 1C antiarrhythmic drugs in patients with coronary artery disease and\/or cardiomyopathy?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}